Insulet Corporation
PODD
$0.92 (0.30%)
1D
1W
3M
1Y
5Y
ALL
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 4 days ago • PODD
Here's Why You Should Retain PODD Stock in Your Portfolio NowMarketBeat • 6 days ago • PODD
3 Medical Technology Stocks Outperforming in 2025Zacks Investment Research • 11 days ago • PODD
Here's Why Insulet (PODD) is a Strong Growth StockZacks Investment Research • 12 days ago • PODD
S&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETFZacks Investment Research • 20 days ago • PODD
Insulet Gains 78.5% in a Year: What's Driving the Stock?Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.